CRYSTALLINE 19-NORSTEROIDS - BRIDGE ORGANICS CO

Title:

CRYSTALLINE 19-NORSTEROIDS

Document Type and Number:

WIPO Patent Application WO2004089970

Kind Code:

A3

Abstract:

The present invention are two crystalline salts, 17alpha-acetoxy-21-methoxy-11ß-(4-,N,N-dimethylaminophenyl)-19 norpregna-4,9-diene-3,20-dione hydrochloride and 17alpha-acetoxy-21-methoxy-11ß-(4-,N,N-dimethylaminophenyl)-19 norpregna-4,9-diene-3,20-dione hydrobromide, of the corresponding free base which is an amorphous solid.

More Like This:

JP2004519439	Dissociated glucocorticoid receptor antagonist for the treatment of glucocorticoid-related side effects
WO/2010/123545	ANGIOGENESIS INHIBITORS
WO/2002/020001	TWO-COMPONENT ANTI-EMETIC COMPOSITION COMPRISING DEXAMETHASONE AND METOCLOPRAMIDE

Inventors:

VAN RHEENEN VERLAN H (US)

Application Number:

PCT/US2004/010352

Publication Date:

February 24, 2005

Filing Date:

April 02, 2004

Export Citation:

Click for automatic bibliography generation Help

Assignee:

BRIDGE ORGANICS CO (US)
VAN RHEENEN VERLAN H (US)

International Classes:

A61K31/56; C07J5/00; C07J; (IPC1-7): C07J5/00

Domestic Patent References:

WO2001047945A1

2001-07-05

Foreign References:

US20020025951A1	2002-02-28
US6768014B2	2004-07-27

Other References:

BERGE ET AL.: "Pharmaceutical salts", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1977, pages 1 - 19, XP000562636

Download PDF:

View/Download PDF PDF Help

Previous Patent: CHOLESTEROL-CONTAINING COMPOUNDS AND THEIR USE AS IMMUNOGENS AGAINST BORRELIA BURGDORFERI

Next Patent: MASS SPECTROMETRY DATA ANALYSIS TECHNIQUES